Home ETF List About

Portfolio Holdings Detail for ISIN IE00B43HR379
Stock Name / FundiShares S&P 500 Health Care Sector UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares V Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300QETNU1W5JY7Z94
ETF TickerIHCU(GBX) LSE
ETF TickerIUHC(USD) LSE
ETF TickerQDVG(EUR) F
ETF TickerIHCU.LS(GBX) CXE
ETF TickerIUHC.LS(USD) CXE
ETF TickerIUHCz(USD) CXE
ETF TickerQDVG.DE(EUR) CXE
ETF TickerIHCU.L(GBP) LSE
ETF TickerIUHC.L(GBP) LSE

Holdings detail for INCY

Stock NameIncyte Corporation
TickerINCY(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS45337C1027
LEI549300Z4WN6JVZ3T4680

Show aggregate INCY holdings

News associated with INCY

Incyte Reaches Analyst Target Price
In recent trading, shares of Incyte Corporation (Symbol: INCY) have crossed above the average analyst 12-month target price of $84.18, changing hands for $84.80/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on v - 2025-09-18 08:17:02
Incyte Reports Encouraging 24-Week Results From Phase 3 STOP-HS Program Of Povorcitinib
(RTTNews) - Incyte Corporation (INCY) on Wednesday announced encouraging 24-week data from the pivotal Phase 3 STOP-HS program evaluating povorcitinib in adults with hidradenitis suppurativa (HS). - 2025-09-17 03:26:09
Incyte Corporation (NASDAQ:INCY) Short Interest Update
Incyte Corporation (NASDAQ:INCY – Get Free Report) was the recipient of a significant increase in short interest during the month of August. As of August 15th, there was short interest totaling 9,600,000 shares, an increase of 29.4% from the July 31st total of 7,420,000 shares. Based on an average trading volume of 1,860,000 shares, the […] - 2025-09-11 04:51:36
Incyte Corporation (NASDAQ:INCY) Receives Consensus Recommendation of “Hold” from Analysts
Incyte Corporation (NASDAQ:INCY – Get Free Report) has been assigned a consensus recommendation of “Hold” from the eighteen analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and seven have issued a buy rating on the company. The […] - 2025-08-26 02:32:54
Incyte (NASDAQ:INCY) Given New $73.00 Price Target at JPMorgan Chase & Co.
Incyte (NASDAQ:INCY – Free Report) had its price objective increased by JPMorgan Chase & Co. from $67.00 to $73.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock. A number of other research firms also recently commented on INCY. Citigroup upped their price objective on […] - 2025-08-25 03:08:46
LABU, INCY, UTHR, REGN: ETF Outflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Direxion Daily S&P Biotech Bull 3x Shares (Symbol: LABU) where we have detected an approximate $67.3 million dollar outflow -- that's a 9.4% dec - 2025-08-20 12:04:03
Charles Schwab Investment Management Inc. Purchases 38,962 Shares of Incyte Corporation (NASDAQ:INCY)
Charles Schwab Investment Management Inc. raised its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 2.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,682,029 shares of the biopharmaceutical company’s stock after purchasing an additional 38,962 […] - 2025-08-13 05:43:01
XBI, ALNY, INSM, INCY: Large Outflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $202.3 million dollar outflow -- that's a 4.3% decrease week over week - 2025-08-12 11:55:54
Citigroup Raises Incyte (NASDAQ:INCY) Price Target to $103.00
Incyte (NASDAQ:INCY – Get Free Report) had its price objective lifted by equities researchers at Citigroup from $88.00 to $103.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s target price suggests a potential upside of 37.54% from the […] - 2025-08-01 04:32:55
Incyte Corporation (NASDAQ:INCY) Receives Consensus Recommendation of “Hold” from Analysts
Shares of Incyte Corporation (NASDAQ:INCY – Get Free Report) have earned a consensus rating of “Hold” from the eighteen research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, twelve have given a hold recommendation and five have assigned a buy recommendation to the […] - 2025-08-01 03:04:43
Incyte Reaches Analyst Target Price
In recent trading, shares of Incyte Corporation (Symbol: INCY) have crossed above the average analyst 12-month target price of $76.09, changing hands for $77.38/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on v - 2025-07-30 10:12:59
Mutual of America Capital Management LLC Sells 478 Shares of Incyte Corporation (NASDAQ:INCY)
Mutual of America Capital Management LLC lessened its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 2.5% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,719 shares of the biopharmaceutical company’s stock after selling 478 shares during the quarter. […] - 2025-07-22 08:02:58
Incyte Corporation (NASDAQ:INCY) Shares Sold by Ballentine Partners LLC
Ballentine Partners LLC trimmed its position in Incyte Corporation (NASDAQ:INCY – Free Report) by 12.2% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 4,686 shares of the biopharmaceutical company’s stock after selling 649 shares during the quarter. Ballentine Partners LLC’s holdings in Incyte were worth $284,000 at the end of the most recent […] - 2025-07-17 05:12:56
Cerity Partners LLC Has $8.04 Million Stock Position in Incyte Corporation (NASDAQ:INCY)
Cerity Partners LLC lifted its holdings in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 103.5% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 132,703 shares of the biopharmaceutical company’s stock after buying an additional 67,495 shares during the period. Cerity Partners LLC owned […] - 2025-07-16 05:40:51
Incyte (NASDAQ:INCY) Price Target Cut to $67.00 by Analysts at JPMorgan Chase & Co.
Incyte (NASDAQ:INCY – Get Free Report) had its price objective decreased by equities research analysts at JPMorgan Chase & Co. from $68.00 to $67.00 in a report released on Monday,Benzinga reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective would suggest a potential downside of […] - 2025-07-16 04:26:52
Sheila A. Denton Sells 599 Shares of Incyte Corporation (NASDAQ:INCY) Stock
Incyte Corporation (NASDAQ:INCY – Get Free Report) EVP Sheila A. Denton sold 599 shares of the company’s stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $68.61, for a total value of $41,097.39. Following the completion of the sale, the executive vice president owned 26,504 […] - 2025-07-09 06:12:52
Incyte Corporation (NASDAQ:INCY) EVP Barry P. Flannelly Sells 10,903 Shares of Stock
Incyte Corporation (NASDAQ:INCY – Get Free Report) EVP Barry P. Flannelly sold 10,903 shares of the stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $68.15, for a total transaction of $743,039.45. Following the sale, the executive vice president directly owned 39,744 shares of the […] - 2025-07-08 06:54:44
Incyte Corporation (NASDAQ:INCY) EVP Sells $587,248.55 in Stock
Incyte Corporation (NASDAQ:INCY – Get Free Report) EVP Vijay K. Iyengar sold 8,617 shares of the company’s stock in a transaction dated Thursday, July 3rd. The stock was sold at an average price of $68.15, for a total transaction of $587,248.55. Following the completion of the sale, the executive vice president directly owned 37,701 shares […] - 2025-07-08 06:20:54
Incyte Corporation (NASDAQ:INCY) Shares Sold by Vontobel Holding Ltd.
Vontobel Holding Ltd. trimmed its holdings in Incyte Corporation (NASDAQ:INCY – Free Report) by 16.8% in the first quarter, Holdings Channel.com reports. The institutional investor owned 7,875 shares of the biopharmaceutical company’s stock after selling 1,592 shares during the quarter. Vontobel Holding Ltd.’s holdings in Incyte were worth $477,000 as of its most recent filing […] - 2025-07-08 04:46:50
Sumitomo Mitsui Trust Group Inc. Purchases 25,844 Shares of Incyte Corporation (NASDAQ:INCY)
Sumitomo Mitsui Trust Group Inc. increased its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 5.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 473,186 shares of the biopharmaceutical company’s stock after purchasing an additional 25,844 shares […] - 2025-07-03 05:25:07
Incyte Corporation (NASDAQ:INCY) Shares Purchased by Chevy Chase Trust Holdings LLC
Chevy Chase Trust Holdings LLC raised its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 0.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 84,241 shares of the biopharmaceutical company’s stock after purchasing an additional 334 shares during the quarter. […] - 2025-06-27 05:36:52
Janney Montgomery Scott LLC Boosts Stock Position in Incyte Corporation (NASDAQ:INCY)
Janney Montgomery Scott LLC grew its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 10.2% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 29,793 shares of the biopharmaceutical company’s stock after purchasing an additional 2,746 shares during the period. Janney Montgomery Scott LLC’s holdings in Incyte were worth $1,804,000 as of its […] - 2025-06-27 04:26:49
State of Alaska Department of Revenue Purchases 590 Shares of Incyte Corporation (NASDAQ:INCY)
State of Alaska Department of Revenue lifted its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 3.2% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 18,824 shares of the biopharmaceutical company’s stock after acquiring an additional 590 shares […] - 2025-06-26 05:56:50
Kentucky Retirement Systems Insurance Trust Fund Makes New Investment in Incyte Corporation (NASDAQ:INCY)
Kentucky Retirement Systems Insurance Trust Fund bought a new stake in Incyte Corporation (NASDAQ:INCY – Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,624 shares of the biopharmaceutical company’s stock, valued at approximately $280,000. A number […] - 2025-06-26 05:03:09
Incyte Corporation (NASDAQ:INCY) Shares Acquired by Wealth Enhancement Advisory Services LLC
Wealth Enhancement Advisory Services LLC lifted its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 66.5% during the 1st quarter, HoldingsChannel.com reports. The fund owned 79,735 shares of the biopharmaceutical company’s stock after acquiring an additional 31,851 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Incyte were worth $4,828,000 […] - 2025-06-26 04:30:52
Assenagon Asset Management S.A. Has $536,000 Stock Position in Incyte Corporation (NASDAQ:INCY)
Assenagon Asset Management S.A. raised its position in Incyte Corporation (NASDAQ:INCY – Free Report) by 37.6% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,846 shares of the biopharmaceutical company’s stock after acquiring an additional 2,418 shares during the period. […] - 2025-06-20 04:54:50
Incyte Corporation (NASDAQ:INCY) Shares Sold by Exchange Traded Concepts LLC
Exchange Traded Concepts LLC lowered its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 41.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 18,117 shares of the biopharmaceutical company’s stock after selling 12,867 shares during the period. Exchange Traded Concepts […] - 2025-06-19 05:43:03
Fifth Third Bancorp Has $551,000 Holdings in Incyte Corporation (NASDAQ:INCY)
Fifth Third Bancorp raised its holdings in Incyte Corporation (NASDAQ:INCY – Free Report) by 2.0% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 9,103 shares of the biopharmaceutical company’s stock after acquiring an additional 179 shares during the quarter. Fifth Third Bancorp’s holdings in Incyte were worth $551,000 at the end of […] - 2025-06-18 04:56:49
Incyte (NASDAQ:INCY) Raised to “Buy” at Stifel Nicolaus
Incyte (NASDAQ:INCY – Get Free Report) was upgraded by equities researchers at Stifel Nicolaus from a “hold” rating to a “buy” rating in a research report issued on Monday, MarketBeat reports. The brokerage currently has a $107.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $75.00. Stifel Nicolaus’ price […] - 2025-06-18 02:22:54
Stocks Settle Higher on Possible De-Escalation of Israel-Iran War
The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.94%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.75%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.42%. June E-mini S&P futures (ESM25 ) are up +1.00%, and June E-mini Nasdaq futures... - 2025-06-17 13:23:43

iShares S&P 500 Health Care Sector UCITS ETF USD (Acc) INCY holdings

DateNumber of INCY Shares HeldBase Market Value of INCY SharesLocal Market Value of INCY SharesChange in INCY Shares HeldChange in INCY Base ValueCurrent Price per INCY Share HeldPrevious Price per INCY Share Held
2025-09-18 (Thursday)75,925INCY holding increased by 89USD 6,529,550INCY holding increased by 98657USD 6,529,55089USD 98,657 USD 86 USD 84.8
2025-09-17 (Wednesday)75,836USD 6,430,893INCY holding increased by 68253USD 6,430,8930USD 68,253 USD 84.8 USD 83.9
2025-09-16 (Tuesday)75,836USD 6,362,640INCY holding increased by 57635USD 6,362,6400USD 57,635 USD 83.9 USD 83.14
2025-09-15 (Monday)75,836USD 6,305,005USD 6,305,005
2025-09-12 (Friday)75,836USD 6,301,972USD 6,301,972
2025-09-11 (Thursday)75,601INCY holding increased by 89USD 6,514,538INCY holding increased by 1628USD 6,514,53889USD 1,628 USD 86.17 USD 86.25
2025-09-10 (Wednesday)75,512INCY holding increased by 89USD 6,512,910INCY holding increased by 56701USD 6,512,91089USD 56,701 USD 86.25 USD 85.6
2025-09-09 (Tuesday)75,423USD 6,456,209INCY holding decreased by -72406USD 6,456,2090USD -72,406 USD 85.6 USD 86.56
2025-09-08 (Monday)75,423USD 6,528,615INCY holding decreased by -6034USD 6,528,6150USD -6,034 USD 86.56 USD 86.64
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of INCY by Blackrock for IE00B43HR379

Show aggregate share trades of INCY

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-09-18BUY89 86.000* 68.99
2025-09-11BUY89 86.170* 68.72
2025-09-10BUY89 86.250* 68.62
2025-08-20BUY176 86.200* 68.12
2025-08-19BUY88 85.460* 68.02
2025-07-17SELL-89 68.940* 68.01 Profit of 6,053 on sale
2025-07-15SELL-356 68.250* 68.00 Profit of 24,209 on sale
2025-07-14SELL-890 69.980* 67.99 Profit of 60,512 on sale
2025-07-09SELL-89 68.720* 67.97 Profit of 6,049 on sale
2025-07-07SELL-178 67.270* 67.97 Profit of 12,099 on sale
2025-07-02BUY89 68.170* 67.97
2025-06-24SELL-1,513 69.010* 67.94 Profit of 102,794 on sale
2025-06-23BUY89 67.260* 67.94
2025-06-20SELL-178 68.460* 67.94 Profit of 12,094 on sale
2025-06-18SELL-89 68.270* 67.94 Profit of 6,046 on sale
2025-06-17BUY1,068 68.810* 67.93
2025-06-13SELL-178 67.750* 67.91 Profit of 12,088 on sale
2025-06-11SELL-89 68.850* 67.89 Profit of 6,043 on sale
2025-06-10SELL-178 70.070* 67.88 Profit of 12,082 on sale
2025-06-09SELL-267 69.890* 67.86 Profit of 18,120 on sale
2025-05-21SELL-89 64.780* 68.08 Profit of 6,059 on sale
2025-05-20SELL-178 65.300* 68.10 Profit of 12,122 on sale
2025-05-15SELL-267 62.760* 68.22 Profit of 18,214 on sale
2025-05-14SELL-267 61.160* 68.28 Profit of 18,229 on sale
2025-05-13BUY89 60.810* 68.34
2025-05-09SELL-89 58.980* 68.48 Profit of 6,095 on sale
2025-05-08BUY178 59.730* 68.55
2025-05-01BUY178 62.030* 68.88
2025-04-24SELL-89 58.970* 69.28 Profit of 6,166 on sale
2025-04-23BUY267 58.000* 69.39
2025-04-15SELL-89 58.460* 70.08 Profit of 6,237 on sale
2025-04-10SELL-174 55.170* 70.48 Profit of 12,263 on sale
2025-04-08SELL-87 56.970* 70.74 Profit of 6,154 on sale
2025-04-07SELL-87 60.290* 70.85 Profit of 6,164 on sale
2025-04-04SELL-174 60.580* 70.96 Profit of 12,346 on sale
2025-04-02BUY87 62.330* 71.05
2025-04-01BUY783 60.910* 71.16
2025-03-31SELL-522 60.550* 71.28 Profit of 37,206 on sale
2025-03-28BUY87 60.600* 71.39
2025-03-26SELL-57 61.260* 71.63 Profit of 4,083 on sale
2025-03-21BUY609 61.920* 71.96
2025-03-20BUY356 60.580* 72.10
2025-03-17SELL-88 62.010* 72.52 Profit of 6,381 on sale
2025-03-12BUY2,435 67.730* 72.70
2025-03-07BUY86 70.790* 72.81
2025-02-28SELL-258 73.500* 72.92 Profit of 18,813 on sale
2025-02-25BUY860 74.400* 72.87
2025-02-20BUY602 71.380* 72.89
2025-02-19BUY258 70.160* 72.93
2025-02-18BUY172 71.270* 72.96
2025-02-13BUY430 70.010* 73.09
2025-02-04BUY344 74.120* 73.27
2025-01-31BUY86 74.160* 73.25
2025-01-29BUY86 73.720* 73.23
2025-01-27BUY172 72.640* 73.24
2025-01-24BUY86 72.590* 73.26
2025-01-22BUY344 72.410* 73.29
2024-12-10SELL-85 72.480* 73.60 Profit of 6,256 on sale
2024-12-09SELL-2,210 72.110* 73.65 Profit of 162,770 on sale
2024-12-03SELL-1,020 72.030* 73.55 Profit of 75,020 on sale
2024-12-02SELL-425 73.240* 73.56 Profit of 31,263 on sale
2024-11-29SELL-86 74.590* 73.52 Profit of 6,323 on sale
2024-11-22SELL-850 71.720* 73.36 Profit of 62,357 on sale
2024-11-21SELL-425 70.390* 73.51 Profit of 31,242 on sale
2024-11-20BUY680 71.050* 73.64
2024-11-18SELL-1,020 76.970* 73.62 Profit of 75,097 on sale
2024-11-11BUY765 81.530* 72.63
2024-11-08SELL-2,720 83.380* 71.87 Profit of 195,477 on sale
2024-11-07SELL-168 82.340* 71.06 Profit of 11,938 on sale
2024-11-01SELL-168 76.130* 68.19 Profit of 11,455 on sale
2024-10-31SELL-344 74.120* 67.44 Profit of 23,201 on sale
2024-10-30BUY85 73.930* 66.52
2024-10-29BUY516 73.600* 65.34
2024-10-28SELL-258 65.690* 65.27 Profit of 16,839 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of INCY

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19321,923395451,11071.4%
2025-09-18244,9471,423469,74752.1%
2025-09-17277,858779546,95350.8%
2025-09-16359,781946576,37962.4%
2025-09-15347,4534582,22859.7%
2025-09-12353,0400631,53455.9%
2025-09-11448,7333,894739,70160.7%
2025-09-10490,727248671,93273.0%
2025-09-09515,3951,822682,79175.5%
2025-09-08308,184119479,82864.2%
2025-09-05256,7192,505512,04950.1%
2025-09-04422,6241,507834,71750.6%
2025-09-03381,6797,777624,92261.1%
2025-09-02547,12015,396816,26767.0%
2025-08-29148,294262304,42748.7%
2025-08-28164,0080347,48047.2%
2025-08-27248,926453513,40148.5%
2025-08-26365,1306709,32051.5%
2025-08-25478,1301,306642,31974.4%
2025-08-22344,3522,023596,30157.7%
2025-08-21198,7294,881335,30159.3%
2025-08-20351,6993,977555,34563.3%
2025-08-19343,1103,146574,32859.7%
2025-08-18366,1244,996653,10356.1%
2025-08-15480,8858,035625,79776.8%
2025-08-14593,55436,654806,06873.6%
2025-08-13845,18198,1601,257,50367.2%
2025-08-12462,89642,208678,68968.2%
2025-08-11385,211696595,89264.6%
2025-08-08248,925738426,18758.4%
2025-08-07268,864929420,48663.9%
2025-08-06554,642891731,48475.8%
2025-08-05361,6872,092623,87958.0%
2025-08-04338,0051,464519,15065.1%
2025-08-01414,814828572,87972.4%
2025-07-31570,8456,148777,41773.4%
2025-07-30471,30314,166881,19453.5%
2025-07-29966,64010,5811,593,70160.7%
2025-07-28382,23662625,51061.1%
2025-07-25216,96749422,99051.3%
2025-07-24348,27623528,51765.9%
2025-07-23297,903583487,29761.1%
2025-07-22267,987172446,48960.0%
2025-07-21223,626380406,72955.0%
2025-07-18241,218108471,58951.2%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.